BIOMAT Database Logo BIOMAT Database Logo

[Inhibition of thrombocyte aggregation by antioxidants]. 1986

K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov

The effects of antioxidants (3-hydroxypyridines, 5-hydroxypyrimidines, hindered phenols) on platelet aggregation were studied. All the compounds under study possessed low anti-aggregation activity against indometacin-sensitive aggregation (activation with arachidonic acid, 50 M). Half-maximal inhibition of aggregation was achieved at a concentration similar to that of the compounds used (10(-3) M in cases of indomethacin-insensitive aggregation, platelet activation by thrombine 1.5 mu/ml and Ca2+-ionophore A23187 1.5 g/ml). 4-methyl-2.6-ditretbutyl phenol (BHT) in the concentration range of 10(-5)-4 X 10(-5) M inhibited and in the concentration range of 4 X 10(-5)-10(-4) M activated indomethacin-sensitive aggregation. The latter effect was not observed in the absence of Ca2+ ions in the incubation medium. It is concluded that the effects of the antioxidants studied on platelet aggregation were due to their non-specific action on platelet membranes.

UI MeSH Term Description Entries
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D016861 Cyclooxygenase Inhibitors Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. Cyclo-Oxygenase Inhibitor,Cyclooxygenase Inhibitor,Prostaglandin Endoperoxide Synthase Inhibitor,Prostaglandin Endoperoxide Synthase Inhibitors,Prostaglandin Synthase Inhibitor,Prostaglandin Synthase Inhibitors,Prostaglandin Synthesis Antagonist,Prostaglandin Synthesis Antagonists,Cyclo-Oxygenase Inhibitors,Inhibitors, Cyclo-Oxygenase,Inhibitors, Cyclooxygenase,Inhibitors, Prostaglandin Synthase,Inhibitors, Prostaglandin-Endoperoxide Synthase,Antagonist, Prostaglandin Synthesis,Antagonists, Prostaglandin Synthesis,Cyclo Oxygenase Inhibitor,Cyclo Oxygenase Inhibitors,Inhibitor, Cyclo-Oxygenase,Inhibitor, Cyclooxygenase,Inhibitor, Prostaglandin Synthase,Inhibitors, Cyclo Oxygenase,Inhibitors, Prostaglandin Endoperoxide Synthase,Synthase Inhibitor, Prostaglandin,Synthesis Antagonist, Prostaglandin

Related Publications

K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Thrombocyte aggregation inhibition].
August 1998, Der Internist,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Inhibition of thrombocyte aggregation by beta blockers. Reduction of collagen-induced thrombocyte aggregation in vitro].
December 1984, Fortschritte der Medizin,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
Inhibition of Protein Aggregation by Several Antioxidants.
January 2018, Oxidative medicine and cellular longevity,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
Inhibition of thrombocyte aggregation by oral motapizone and other drugs.
January 1986, European journal of clinical pharmacology,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[In-vitro inhibition of thrombocyte aggregation induced by xenogenic serum].
January 1972, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
February 2006, Deutsche medizinische Wochenschrift (1946),
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Inhibition of thrombocyte aggregation after heart valve replacement].
January 1998, Zeitschrift fur Kardiologie,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Inhibition of thrombocyte aggregation as a therapeutic principle. Review of the literature and currently approved thrombocyte aggregation inhibitors].
April 2000, Der Internist,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Experimental studies on the mechanism of thrombocyte aggregation inhibition caused by sulfonylurea compounds. 2. Modification of blood sugar and thrombocyte aggregation by oral antidiabetics].
February 1975, Arzneimittel-Forschung,
K O Muranov, and S B Gashev, and L D Smirnov, and A A Shvedova, and V B Ritov
[Inhibition of induced thrombocyte aggregation by adenosine and adenosine derivatives. 2. Correlation between inhibition of aggregation and peripheral vasodilatation].
November 1970, Arzneimittel-Forschung,
Copied contents to your clipboard!